StreetInsider.com News Articles

Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26889179.html

Form SCHEDULE 13G Sarepta Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 10:55:00 -0400

si-local-file:///var/storage/secattach/20260807/26889179.html

Sarepta Therapeutics (SRPT) PT Lowered to $35 at Oppenheimer

Thu, 06 Aug 2026 08:37:56 -0400

Oppenheimer analyst Andreas Argyrides lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $35.00 (from $37.00) while maintaining a Outperform rating.

Sarepta Therapeutics (SRPT) Tops Q2 EPS by 42c, Beats on Revenue

Wed, 05 Aug 2026 16:35:07 -0400

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $0.64, $0.42 better than the analyst estimate of $0.22. Revenue for the quarter came in at $401.3 million versus the consensus estimate of $383 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

Form 8-K Sarepta Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874037.html

Form 8-K Sarepta Therapeutics, For: Aug 05

Wed, 05 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260805/26874037.html

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026.

“As I begin my

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

“As I begin my

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

“As I begin my

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Wed, 05 Aug 2026 16:05:00 -0400

New CEO Michael Severino, MD, brings extensive biopharma leadership and a proven track record of advancing innovation, building franchises, and delivering growth

Net product revenues for the second quarter 2026 totaled $328.7 million, consisting of $230.6 million of PMO net product revenue and $98.1 million of ELEVIDYS net product revenue

Achieved GAAP and non-GAAP operating income of $13.3 million and $86.5 million for the second quarter 2026, respectively

“As I begin my

Form 10-Q Sarepta Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260805/AJ22W22FZW2R52ZK222C22YJEUVDYZ22Z282

Filed on: August 5, 2026

Form 10-Q Sarepta Therapeutics, For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400

http://archive.fast-edgar.com/20260805/AJ22W22FZW2R52ZK222C22YJEUVDYZ22Z282

Filed on: August 5, 2026

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260731/26848923.html

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:40:00 -0400

si-local-file:///var/storage/secattach/20260731/26848923.html

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:19:00 -0400

si-local-file:///var/storage/secattach/20260730/26841270.html

Form SCHEDULE 13G/A Sarepta Therapeutics, Filed by: BlackRock, Inc.

Thu, 30 Jul 2026 11:19:00 -0400

si-local-file:///var/storage/secattach/20260730/26841270.html

Form 4 Sarepta Therapeutics, For: Jul 28 Filed by: SEVERINO MICHAEL

Wed, 29 Jul 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260729/26836885.html

Form 4 Sarepta Therapeutics, For: Jul 28 Filed by: SEVERINO MICHAEL

Wed, 29 Jul 2026 20:05:00 -0400

si-local-file:///var/storage/secattach/20260729/26836885.html

Form 3 Sarepta Therapeutics, For: Jul 28 Filed by: SEVERINO MICHAEL

Wed, 29 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26836868.html

Form 3 Sarepta Therapeutics, For: Jul 28 Filed by: SEVERINO MICHAEL

Wed, 29 Jul 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26836868.html

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 29 Jul 2026 17:00:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to employment to Michael Severino, M.D. as Chief Executive Officer of Sarepta. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Dr. Severino received options to purchase 2,224,342 shares of Sarepta’s common stock (“Options”), and 756,104 restricted stock units (“RSUs”). The options have an exercise price of $17.74 per share,

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 29 Jul 2026 17:00:00 -0400

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 29 Jul 2026 17:00:00 -0400

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 29 Jul 2026 17:00:00 -0400

Form S-8 Sarepta Therapeutics,

Tue, 28 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260728/26828343.html